2,893 Shares in Amgen Inc. $AMGN Acquired by Ausdal Financial Partners Inc.

Key Points

• Ausdal Financial Partners acquired 2,893 Amgen shares during the second quarter, valued at approximately $1.05 million. Institutional investors collectively own 76.5% of Amgen’s outstanding stock.
• Analyst sentiment remains mixed, with an overall “Hold” rating and an average price target of $380.43. UBS raised its target to $440 and maintained a “Buy” rating, while Bank of America maintained an “Underperform” rating.
• Amgen exceeded quarterly expectations, reporting $6.29 in EPS and $10.05 billion in revenue, while revenue rose 9.5% year over year. The company also declared a quarterly dividend of $2.52 per share, representing a 2.3% annualized yield.

Ausdal Financial Partners Inc. acquired a new stake in Amgen Inc. (NASDAQ:AMGN - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 2,893 shares of the medical research company's stock, valued at approximately $1,048,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Dogwood Wealth Management LLC increased its position in shares of Amgen by 275.0% during the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company's stock valued at $25,000 after buying an additional 55 shares during the period. Anfield Capital Management LLC boosted its position in shares of Amgen by 1,000.0% in the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company's stock valued at $25,000 after acquiring an additional 70 shares during the period. Tower View Wealth Management LLC grew its stake in Amgen by 331.6% during the first quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company's stock valued at $29,000 after acquiring an additional 63 shares in the last quarter. Manning & Napier Advisors LLC grew its stake in Amgen by 49.2% during the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company's stock valued at $32,000 after acquiring an additional 32 shares in the last quarter. Finally, Ares Financial Consulting LLC bought a new stake in Amgen during the 4th quarter worth approximately $34,000. 76.50% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research analysts have commented on the stock. The Goldman Sachs Group set a $389.00 price target on shares of Amgen in a report on Friday, June 5th. Bank of America upped their price target on shares of Amgen from $312.00 to $317.00 and gave the stock an "underperform" rating in a report on Wednesday, August 5th. Canaccord Genuity Group increased their price objective on Amgen from $366.00 to $384.00 and gave the stock a "hold" rating in a research report on Wednesday, August 5th. Sanford C. Bernstein lifted their price objective on Amgen from $335.00 to $345.00 and gave the company a "market perform" rating in a research note on Thursday, August 6th. Finally, UBS Group boosted their target price on Amgen from $420.00 to $440.00 and gave the stock a "buy" rating in a research report on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, fourteen have given a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $380.43.

Amgen Trading Down 0.4%

NASDAQ AMGN opened at $440.34 on Thursday. The company has a quick ratio of 1.13, a current ratio of 1.37 and a debt-to-equity ratio of 4.44. The stock's 50-day simple moving average is $384.76 and its two-hundred day simple moving average is $363.86. Amgen Inc. has a twelve month low of $269.77 and a twelve month high of $447.03. The company has a market capitalization of $238.06 billion, a price-to-earnings ratio of 27.37, a PEG ratio of 3.19 and a beta of 0.41.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.62 by $0.67. The firm had revenue of $10.05 billion during the quarter, compared to analysts' expectations of $9.43 billion. Amgen had a return on equity of 124.14% and a net margin of 22.95%.The company's revenue for the quarter was up 9.5% compared to the same quarter last year. During the same period in the prior year, the business earned $6.02 EPS. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Research analysts forecast that Amgen Inc. will post 22.92 EPS for the current fiscal year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 11th. Shareholders of record on Friday, August 21st will be given a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date is Friday, August 21st. Amgen's dividend payout ratio (DPR) is presently 62.65%.

Insider Buying and Selling

In other news, SVP Rachna Khosla sold 2,000 shares of the company's stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $412.57, for a total value of $825,140.00. Following the completion of the sale, the senior vice president owned 6,404 shares of the company's stock, valued at approximately $2,642,098.28. This represents a 23.80% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Nancy A. Grygiel sold 2,970 shares of Amgen stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the completion of the transaction, the senior vice president owned 7,340 shares in the company, valued at approximately $2,951,854.40. The trade was a 28.81% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 6,222 shares of company stock worth $2,540,926 over the last quarter. Company insiders own 0.85% of the company's stock.

Amgen Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source